2B yuan financing can't buy an annual report: The suspension mystery behind Mirui's $14.8 million prepayment

On April 2, 2026, MiRui (02629.HK) released an announcement disclosing the core details behind the suspension. Its auditor, KPMG, found 14 prepaid items totaling approximately $14.8 million during its review of the company’s 2025 annual report. Of this amount, about $9.5 million had already been refunded by the relevant service providers, and the remaining approximately $5.3 million was for prepaid expenses related to work that had been completed or was underway. The company also announced the establishment of an independent investigation committee and appointed a law firm and professional institutions to assist in the review.

Just one day earlier, at 9:00 a.m. on April 1, this listed biotech company, which had been public for less than a year, was formally suspended by the Hong Kong Stock Exchange for failing to publish the audited annual report on time. The $14.8 million “audit question” quickly became a market focus. This 18A newcomer that listed on the main board of the Hong Kong Stock Exchange only on May 23, 2025—still less than one year after listing—stepped over the suspension red line due to “annual report delays,” echoing Noevir Health and again putting financial compliance anxieties in the tumor early screening early detection sector in the spotlight.

This is not an isolated case. More than 20 Hong Kong-listed companies suspended trading for the same reason that day. With the auditing environment being tightened across the board, MiRui’s suspension looks more like a snapshot of a system-wide compliance stress test.

$14.8 million under audit

Starting at 9:00 a.m. on April 1, 2026, MiRui Shares suspended trading on the Hong Kong Exchanges and Clearing Limited (HKEX). The company said in its announcement that it could not publish its 2025 annual results by the March 31 deadline because the auditors needed more time to assess certain prepaid amounts paid by the company to service providers and suppliers.

Under the HKEX’s Listing Rules, failing to publish an audited annual report on time results in a compulsory suspension of trading. If the suspension lasts more than 18 months, there will be delisting risk.

The next day, MiRui’s announcement disclosed further details: during the audit process, KPMG identified 14 prepaid expense items, involving payments the company made to service providers and suppliers. Most occurred in the second half of 2025, with a total value of approximately $14.8 million. As of the date of the announcement, about $9.5 million had been refunded by the relevant service providers and suppliers, and the remaining approximately $5.3 million related to prepaid expenses for work that had been completed or was underway. Meanwhile, MiRui’s board approved the establishment of an independent investigation committee, led by two independent non-executive directors, Lin Qianli and Fang Xiaoqian, and appointed a law firm and professional investigation institutions to assist with the review. The company emphasized that the transactions requiring additional review in this case have no direct relationship with the company’s R&D, commercial operations, or related technical platforms. The company also stated that its day-to-day operations are proceeding normally and have not been affected.

It is worth noting that MiRui is not the only company “tripping up” during the annual report season. Data shows that on April 1, more than 20 Hong Kong-listed companies collectively suspended trading because they failed to publish their 2025 annual results on time. The list includes China Hui Bio-B, Contemporary Properties, Shanghai Xiaonan Guo, Shenghe Bio-B, HeXingChuangzhan Group, and several other companies across different industries. Behind this phenomenon is the notable tightening of the audit environment in Hong Kong stocks. Affected by events such as PricewaterhouseCoopers (PwC) resigning from the audit work for some Hong Kong-listed companies, the “Big Four” audit firms—including KPMG—have generally increased their scrutiny of audit compliance requirements. Their investigation into key financial line items such as prepayments and related-party transactions has been clearly strengthened. Insiders point out that audit firms no longer limit themselves to matching contract and cash-flow ledgers on paper; instead, they are moving toward more stringent cross-border, penetration-style confirmations. Prepayment review has become one of the common reasons for annual report delays.

MiRui’s suspension inevitably sparked market speculation alongside Noevir Health. Noevir Health, the former “number-one early screening stock” with a market cap of over HK$30 billion, faced allegations of sales fraud after a short-seller challenged it in 2023. Subsequently, its auditor, Deloitte, refused to issue an annual report opinion, directly pointing to the authenticity of revenue. In the end, Noevir Health was forcibly delisted in October 2025. However, multiple market participants noted that the two cases are fundamentally different. Noevir Health’s core issue was “the authenticity of revenue,” which is malicious financial fraud involving fabricated performance. By contrast, MiRui’s current review focuses on the expenditure-side line item of “prepayments.” This is an operational prepayment by the company. The delay occurred only because, under a backdrop of tightened regulation, the audit firm needed more time to verify materials. The nature is completely different.

One detail worth probing further is: why did MiRui experience the cancellation of projects totaling nearly $1.09B and the refund of prepayments? The company’s explanation was “some projects were canceled.” This raises deeper questions: MiRui listed in May 2025, raising HK$1.09B. After listing, the project timeline accelerated sharply. Why were multiple new projects canceled within just half a year? Was it due to overly hasty project approvals, or did major changes occur in the external business environment that were not disclosed? This may be the key set of doubts indicated by the 14 transactions that the independent investigation committee needs to focus on reviewing.

A gap between $2 billion in financing and $3.7 billion in market value

Before the suspension controversy, MiRui’s 2025 interim performance had highlights. In the first half of the year, revenue was $10.47 million, up 9.4% year over year; gross profit was $7.10 million, up 51.1%; and loss attributable to equity shareholders was $28.35 million, significantly narrowed from $44.45 million in the same period last year. The gross margin rose from 49% to 67.6%. The performance growth mainly benefited from the performance of early detection and precision multi-omics businesses. Its core products, GASTROClear™ and LUNGClear™, performed strongly in sales within the Asian cancer diagnosis market.

However, when looking over a longer horizon, MiRui’s financial position shows clear fluctuations. In 2021, due to a sales peak for its COVID-19 testing product Fortitude, full-year revenue reached $60.6498 million. Thereafter, as the pandemic improved, 2022 revenue fell sharply to $17.7590 million. Revenue rebounded to $24.1850 million in 2023, but dropped again to $20.2827 million in 2024. Meanwhile, losses continued to widen. From 2022 to 2024, losses were $56.2027 million, $69.5693 million, and $92.2147 million respectively, for cumulative losses of about $218 million over the three years. Although losses in the first half of 2025 narrowed, they were still at a level close to $30 million.

What is intriguing is that just three months before the suspension, MiRui was displaying a “high spot” moment in the capital market. On January 29, 2026, the company completed a new share placement, raising approximately HK$711 million. The placing price was HK$32.5 per share, representing a premium of nearly 40% compared with the IPO offering price of HK$23.30 per share in May 2025. Together with the IPO funds raised of HK$1.086 billion, MiRui’s cumulative financing over the 8 months since listing totaled nearly HK$2 billion. This was quite eye-catching among Hong Kong biopharma companies in recent years. However, the impressive financing performance did not support the share price. As of the trading day immediately before the suspension (March 31), MiRui’s stock closed at HK$12.41 per share, with a total market capitalization of about HK$3.7 billion, nearly halving from the more than HK$8 billion market cap at the beginning of listing. More severely, this market value had already fallen well below the daily market capitalization floor of HK$5 billion for Hang Seng Composite SmallCap companies under the Stock Connect program. This means the company was effectively no longer eligible for allocation by mainland funds via Stock Connect, and future financing and trading liquidity would face further pressure.

From the perspective of the product pipeline, MiRui has indeed built differentiated technical barriers in the miRNA liquid biopsy field. As of June 30, 2025, the company had its core product GASTROClear™ (the world’s first approved IVD molecular diagnostic product for gastric cancer screening), two other commercial products, LUNGClear™ and Fortitude™, and six candidate products in preclinical stages. GASTROClear™ was approved for listing in Singapore in May 2019. In October 2025, it obtained China’s NMPA Class III medical device registration certificate, becoming the first non-invasive test product in China specifically for gastric cancer early screening indications. In March 2026, the company successfully won the bid for the gastric cancer screening and early intervention project in Lianxi District, Jiujiang City, Jiangxi Province, marking that the core product had entered the implementation stage in the Chinese market. However, technical barriers do not necessarily translate into commercial success. In the current environment of strict regulation for Hong Kong stocks, financial authenticity and internal control compliance have become more of a bottom line for corporate survival than pipeline stories and faster commercialization growth.

KPMG’s conclusion is the real variable

The biggest uncertainty regarding MiRui’s resumption of trading lies in the final conclusion of the auditors’ “additional assessment.” Zeng Siqiao, a lawyer at Hunan Kuangzhen Law Firm and an expert in securities litigation, said, “For certain key financial data, there must be some differences between the auditors’ and the company’s audit positions, and that may affect the true reliability of MiRui’s full-year performance data.” Bai Wenxi, deputy chairwoman of the China Enterprise Capital Alliance, analyzed that the greatest uncertainty in the resumption is whether the auditors’ conclusion is merely an accounting treatment adjustment, or whether they have found more serious internal control failures or signs of fraud. “If it turns out to be the latter, it may trigger disciplinary investigations by the HKEX, or even referral to the China Securities Regulatory Commission, and the path to resumption of trading could be long. In addition, whether the company can maintain operating funds during the suspension period (especially when it has just completed the placement and had ample funding, which should have been an advantage) is also critical.”

As of the time of publication, MiRui’s independent investigation is still ongoing, and KPMG’s audit work has not been completed. On the positive side, after the incident, MiRui proactively established an independent investigation committee. This is not a mandatory requirement under HKEX regulatory rules, showing the company’s determination to push for an early resumption of trading. However, neither the independent investigation nor the audit has been settled, and the suspension status is still continuing. Investors’ patience is limited. Under HKEX rules, trading will be suspended beyond 18 months and will result in delisting. “The precondition for a resumption of trading is that MiRui must publish an audited annual report, and the auditors must no longer issue a qualified opinion or an inability to express an opinion on the prepayment matters. It must prove that the prepayment items have commercial substance, are recoverable, and that internal control rectification has been completed. If there is any misappropriation of funds or related-party transactions, repayment and corrective disclosures must be completed.” Bai Wenxi emphasized that whether these conditions are met will become the core variable determining whether MiRui can resume trading in the near term.

In response to the above issues, a reporter from the Huaxia Times attempted to contact MiRui for an interview, but as of the time of publication, no reply had been received.

A vast amount of information and precise analysis—All available on the Sina Finance APP